Molecular Templates Announces Partial Clinical Hold for Phas

Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169

08.04.2023 - Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose cohortsAUSTIN, Texas, April 07, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or ... Seite 1

Related Keywords

Roger Waltzman , , Molecular Templates , Multiple Myeloma , Very Good Partial Response , Chief Medical Officer ,

© 2025 Vimarsana